AGTC Genomics Partners with a Leading Health Insurance Provider to Reduce Rising Medical Costs Through Precision Medicine and Early Cancer Detection

Kuala Lumpur, Malaysia – 5 May 2026 – In a significant step toward transforming healthcare affordability and improving patient outcomes in Malaysia, AGTC Genomics has announced a strategic partnership with a leading health insurance provider to make advanced precision medicine and early cancer detection tests fully claimable under selected insurance plans.

Through this initiative, Malaysians can now gain greater access to critical genomic testing services including Multi-Cancer Early Detection (MCED), Comprehensive Gene Profiling (CGP), Liquid Biopsy, and Pharmacogenomics (PGx) testing—powerful tools designed to detect disease earlier, guide more effective treatments, and prevent unnecessary healthcare costs caused by delayed diagnosis or ineffective therapy.

Importantly, these are doctor-prescribed clinical tests, ensuring appropriate medical oversight, interpretation, and follow-up care. Patients can access these tests through their treating physicians, and they can be ordered by doctors in most clinics, specialist centers, and hospitals nationwide across Malaysia, making precision medicine increasingly accessible as part of routine healthcare.

The partnership reflects a growing recognition that the future of healthcare is not only about treatment, but prevention, prediction, and personalization.

Cancer and chronic diseases remain among the leading contributors to rising healthcare expenditure in Malaysia. Many patients are diagnosed only at advanced stages, where treatment becomes significantly more complex, expensive, and often less effective. Precision medicine offers a new pathway—intervening earlier, selecting the right treatment from the start, and avoiding costly trial-and-error approaches.

According to Prof. Dr. Chee-Onn Leong, Founder and CEO of AGTC Genomics, this model creates value for all stakeholders across the healthcare ecosystem.

“Healthcare should not begin only when a patient becomes critically ill. It should begin much earlier—with prevention, early detection, and precision intervention. This is where genomics creates real impact. When cancer is detected at Stage 1 instead of Stage 4, the difference is not only survival—it is also the difference between affordable treatment and catastrophic medical costs. When the right targeted therapy is chosen from the beginning through comprehensive gene profiling, patients avoid ineffective treatments, unnecessary toxicity, and wasted time. Pharmacogenomics helps us prescribe the right drug at the right dose for the right patient, reducing adverse drug reactions and hospitalizations. This is good for patients, good for insurers, and good for the sustainability of the national healthcare system.”

Under the partnership, eligible policyholders can now claim these advanced genomic tests as part of their medical coverage, removing one of the biggest barriers to adoption—cost accessibility.

This includes:

• Multi-Cancer Early Detection (MCED): blood-based screening capable of identifying signals from multiple cancers before symptoms appear

• Comprehensive Gene Profiling (CGP): advanced tumor profiling to guide targeted therapy and immunotherapy decisions

• Liquid Biopsy: non-invasive cancer testing using blood samples for diagnosis, treatment monitoring, and minimal residual disease detection

• Pharmacogenomics (PGx): genetic testing to optimize medication selection and dosing based on individual DNA profiles

Because these are physician-led clinical diagnostics, results are interpreted within the proper medical context, allowing doctors to make faster, more precise decisions for patient management and treatment planning.

Unlike many outsourced genomic services, all tests are performed locally at AGTC Genomics’s Advanced Genomics Laboratory in Malaysia, which is both ISO 15189-accredited and CAP-accredited (College of American Pathologists)—ensuring international-quality standards for clinical diagnostics.

This local testing capability eliminates the need to send samples overseas, significantly reducing turnaround time, improving physician decision-making speed, and ensuring faster access to treatment when time matters most.

It also supports Malaysia’s broader ambition to strengthen national healthcare resilience and reduce dependence on foreign diagnostic services.

As Malaysia moves toward a more sustainable and equitable healthcare future, this collaboration between genomics and insurance marks an important shift—from paying for late-stage disease to investing in early intervention and better outcomes.

The most expensive disease is the one we detect too late. Precision medicine is not a luxury—it is a necessity for modern healthcare. The goal is simple: detect earlier, treat smarter, save lives, and reduce costs. When advanced genomics becomes accessible to everyone—not just a privilege for a few—we create a healthcare system that is better, and fairer. The future of medicine is not reactive. It is predictive, preventive, and personal. That future starts now.

---

About AGTC Genomics

AGTC Genomics is one of Southeast Asia’s leading precision medicine and genomics companies, providing advanced genomic diagnostics for oncology, rare diseases, preventive health, reproductive health, and personalized medicine. With one of the region’s largest genomics sequencing facilities and the only ISO15189, ISO17025 and CAP triple-accredited laboratory in Malaysia for precision medicine, AGTC Genomics is committed to making precision medicine more accessible, affordable, and impactful for patients across Asia.